Abstract | OBJECTIVE: METHODS: RESULTS: Hematopoiesis recovery was observed in all the AHBI patients. The 3-year disease free survival (DFS) rate and the AHBI-related mortality were (52.38 +/- 13.47)% and 0, respectively. The longest survival time was 1446 days with a median follow-up period of 927 (428 approximately 1446) days. The 3-year DFS for the 11 acute lymphocytic leukemia (ALL) patients was (47.73 +/- 17.55)%. By contrast, the 3-year DFS and the AHSCT-related mortality for the 14 ALL patients in the control AHSCT group were (53.88 +/- 14.08)% and 14%, respectively. There was no significant difference in 3-year DFS between AHBI and AHSCT ALL patients. CONCLUSIONS:
|
Authors | Jia-Lin Wei, Mei Wang, De-Hui Zou, Dong-Lin Yang, Rui Li, Jun Ning, Si-Zhou Feng, Ming-Zhe Han |
Journal | Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
(Zhonghua Xue Ye Xue Za Zhi)
Vol. 25
Issue 6
Pg. 355-8
(Jun 2004)
ISSN: 0253-2727 [Print] China |
PMID | 15308016
(Publication Type: English Abstract, Journal Article)
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Female
- Hematologic Neoplasms
(drug therapy, radiotherapy)
- Hemibody Irradiation
(adverse effects, methods)
- Humans
- Male
- Middle Aged
- Treatment Outcome
|